Seagen
Seagen, now part of Pfizer, is a global biotechnology company pioneering antibody-drug conjugates (ADCs) to revolutionize cancer care. Their innovative therapies target solid tumors and blood-related cancers, with a strong commitment to diversity, equity, and inclusion.
Seagen's Acquisition by Pfizer
Seagen is now part of Pfizer, a global leader in the pharmaceutical industry. This acquisition allows Seagen to leverage Pfizer's extensive resources and expertise, enhancing its ability to bring innovative cancer treatments to patients worldwide.
Seagen's Antibody-Drug Conjugates (ADCs)
Seagen has been a pioneer in the development of antibody-drug conjugates (ADCs) for over 20 years. ADCs are designed to deliver potent cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Seagen's ADC technology harnesses the power of potent payloads and the specificity of antibodies to treat various cancers, including solid tumors and blood-related cancers.
Seagen's Medicines and Cancer Treatments
Seagen has developed a range of medicines targeting different types of cancer. These include ADCETRIS® (brentuximab vedotin) for Hodgkin lymphoma, PADCEV® (enfortumab vedotin-ejfv) for urothelial cancer, TIVDAK® (tisotumab vedotin-tftv) for cervical cancer, and TUKYSA® (tucatinib) for HER2-positive breast cancer. These therapies represent significant advancements in treating these cancers.
Seagen's Research and Development Pipeline
Seagen's research pipeline includes various programs focused on advancing innovative therapies for cancer patients. The company's efforts feature its proprietary ADC technologies, novel antibodies, and other targeted cancer therapeutics. Seagen conducts numerous clinical trials aimed at developing new treatments to improve outcomes for cancer patients worldwide.
Seagen's Commitment to Corporate Responsibility
Seagen is dedicated to corporate responsibility, encompassing environmental sustainability, social responsibility, and strong governance. The company supports diversity, equity, and inclusion within its workforce and leadership. Additionally, Seagen actively supports patient advocacy organizations and initiatives, alongside its Investigator-Sponsored Trials (IST) and Translational Research Agreement (TRA) programs to advance medical and scientific knowledge.